Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S M Proudman

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
The Journal of Rheumatology|March 1, 1994
Effect of exercise on 99mTc-DTPA clearance from knees with effusionsM J James, L G Cleland, R D Gaffney, et al.
Immunology and Cell Biology|August 8, 2001
Recruitment of mononuclear leucocytes to osteoarthritic human synovial xenografts in the ears of SCID miceL G Cleland, M Fusco, S M Proudman, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 31, 2015
Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis PatientsA M Hopkins, M D Wiese, S M Proudman, et al.
The Pharmacogenomics Journal|January 8, 2014
Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritisM D Wiese, N Alotaibi, C O'Doherty, et al.
Arthritis Care & Research|October 16, 2013
Decline in hand bone mineral density indicates increased risk of erosive change in early rheumatoid arthritisR J Black, L Spargo, C Schultz, et al.
Internal Medicine Journal|May 15, 2013
Should patients with systemic sclerosis-related pulmonary arterial hypertension be anticoagulated?M Nikpour, W Stevens, S M Proudman, et al.
Internal Medicine Journal|April 18, 2009
Treatment-induced stable, moderate reduction in blood cell counts correlate to disease control in early rheumatoid arthritisS E Lester, S M Proudman, A T Y Lee, et al.
Journal of Clinical Pharmacy and Therapeutics|July 22, 2014
The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicityA M Hopkins, C E O'Doherty, D J R Foster, et al.
International Journal of Clinical Practice|March 19, 2016
Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term?N Wabe, M J Sorich, M D Wechalekar, et al.
Scandinavian Journal of Rheumatology|April 14, 2021
Anti-Ro52/TRIM21 is independently associated with pulmonary arterial hypertension and mortality in a cohort of systemic sclerosis patientsAys Lee, K A Patterson, D J Tan, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
The Journal of Rheumatology|March 1, 1994
Effect of exercise on 99mTc-DTPA clearance from knees with effusionsM J James, L G Cleland, R D Gaffney, et al.
Immunology and Cell Biology|August 8, 2001
Recruitment of mononuclear leucocytes to osteoarthritic human synovial xenografts in the ears of SCID miceL G Cleland, M Fusco, S M Proudman, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 31, 2015
Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis PatientsA M Hopkins, M D Wiese, S M Proudman, et al.
The Pharmacogenomics Journal|January 8, 2014
Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritisM D Wiese, N Alotaibi, C O'Doherty, et al.
Arthritis Care & Research|October 16, 2013
Decline in hand bone mineral density indicates increased risk of erosive change in early rheumatoid arthritisR J Black, L Spargo, C Schultz, et al.
Internal Medicine Journal|May 15, 2013
Should patients with systemic sclerosis-related pulmonary arterial hypertension be anticoagulated?M Nikpour, W Stevens, S M Proudman, et al.
Internal Medicine Journal|April 18, 2009
Treatment-induced stable, moderate reduction in blood cell counts correlate to disease control in early rheumatoid arthritisS E Lester, S M Proudman, A T Y Lee, et al.
Journal of Clinical Pharmacy and Therapeutics|July 22, 2014
The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicityA M Hopkins, C E O'Doherty, D J R Foster, et al.
International Journal of Clinical Practice|March 19, 2016
Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term?N Wabe, M J Sorich, M D Wechalekar, et al.
Scandinavian Journal of Rheumatology|April 14, 2021
Anti-Ro52/TRIM21 is independently associated with pulmonary arterial hypertension and mortality in a cohort of systemic sclerosis patientsAys Lee, K A Patterson, D J Tan, et al.
Pageof 3